Scaleup Europe Fund

From lab to market: Strengthening the role of Technology Transfer Offices in bringing knowledge to the market is sponsored by European Commission — Horizon Europe. Expected Outcome: Project results are expected to contribute to the following outcomes: Increased commercialisation of academic research results, by facilitating access for industry, startups and scaleups to the intellectual assets of academic research; Strengthened collaboration between industry and academia, reflected in an increased number of technology transfer deals and joint R&D projects resulting in market-ready innovations; Introduced more startup friendly intellectual asset transfer/licensing policies in universities/research and higher education institutions/RTOs; Increased number of spinoffs by enabling researchers to overcome the barriers to commercialising their intellectual assets; Reduced transaction costs related to Intellectual Property Rights (IPR) negotiations by establishing more standardised asset transfer policies across universities/research and higher education institutions/RTOs; Optimised transfer/licensing processes by universities/research and higher education institutions/RTOs based on grouping intellectual assets in portfolios that can be commercialised in package deals that are more attractive for industry and investors. Scope: Academic knowledge producing organisations (universities, research and higher education institutions and RTOs) are acting as innovation engines by fuelling startups and industries with new knowledge, technologies and skilled individuals. This potential can be nurtured with efficient intellectual management strategies and effective Technology Transfer Offices (TTOs). However, Europe’s potential of research valorisation is underutilised. Currently, it is challenging for industrial actors to identify and access academic results that have potential for commercialisation. On the one hand, a relatively complex fragmented landscape of TTOs generates high transaction costs discouraging companies, especially startups from engaging in collaboration or accessing academic research for commercialisation. On the other hand, the lack of financial and non-financial incentives for academic researchers hampers their commitment. Indeed, in many cases, researchers cannot fully appropriate royalties from the licensing of intellectual assets and knowledge valorisation activities are not recognised for their career progression. In this regard, the Draghi report [1] recommends European universities/RTOs to adopt a more coordinated, commercialisation minded, and startup friendly intellectual asset management approach [2] . Participating beneficiaries should engage in the following activities: adopting startup-friendly intellectual asset management strategies; accelerating the commercialisation of academic research results under fair and transparent conditions in an attractive way for innovative companies and investors, in particular for critical technology areas related to the EU’s economic security; reinforcing the adoption of best practices in intellectual asset management [3] including the equitable sharing of value generated in R&I activities; improving the support to researchers and students in commercialising research results; enhancing intellectual asset management practices by establishing portfolio approaches to market intellectual assets in package deals; facilitating the collaboration between researchers, startups and innovative companies. More specifically, project participants should: Identify and share best-practices developed to support knowledge valorisation [4] ; On this basis, create a common set of tools for start-up friendly licensing/transfer [5] to be adapted to the specific national/regional context with templates, strategies, successful case studies and business models. The toolbox could include standardised rules and processes together with flexible and adaptable clauses to support negotiation, conclusion and implementation of licensing agreements; Develop a common incentives and benefit-sharing model ensuring incentives for researchers and students to engage in com Programme areas: Horizon Europe (HORIZON), Innovative Europe, European innovation ecosystems Keywords: IPR management, Market-creating innovation, Technology transfer

Diversification of nutritional food ingredient sources for increased EU resilience and strategic autonomy is sponsored by European Commission — Horizon Europe. Expected Outcome: Successful proposals will contribute to the implementation of the EU initiative on Biotechnology and Biomanufacturing and the EU Life Sciences Strategy as well as the updated EU Bioeconomy Strategy, the upcoming EU Biotechnology Act and EU Circular Economy Act. Projects’ results are expected to contribute to the following expected outcomes: Full industrial scale biorefinery and related value chain(s) for the production of nutritional food ingredients. Resilience and strategic autonomy of EU food sectors via diversification of nutritional food ingredient sources. Increased environmental sustainability of food sectors (e.g. addressing issues like land use, water use, energy consumption, nitrogen cycle, other nutrients, etc.). Improved consumers awareness and acceptance of nutritional food ingredients from alternative sources, contributing to sustainable healthy diets. Scope: Human nutrition is a key area where the bio-based industries can play an important role in addressing the present societal and climate challenges. Considerable attention is given to the utilisation of alternative sources of proteins, fibres and oils/fats, due to the increasing world population and the pressure on finite natural resources. Many sources for food ingredients, alternative to agricultural crops, exist and have been successfully piloted across the EU. However, efforts are needed to scale up sustainable processes to achieve adequate or even improved nutritional properties, ensure safety and consumers/end users acceptance, while achieving cost competitiveness. Proposals under this topic should: Demonstrate (at TRL 8) the efficient production of nutritional ingredients for food applications. Proteins, lipids, specialty carbohydrates, and fibres are in scope. Target at least one of these as the main product driving the business case. Structural or functional ingredients such as colourants, preservatives, stabilisers, texturisers, enzymes are not in scope as the main product. Synergistic co-production of multiple and different food and feed ingredients and other bio-based products is also in scope following the cascading approach. All sources of bio-based feedstock [1] are in scope. Direct production of food from food crops, livestock, fisheries and aquaculture is not in scope. The use of industrial grade feedstock [2] from agricultural crops is in scope for conversion into food grade ingredients. Validate (at TRL 6 and above) the use of the obtained nutritional food ingredient(s) into the formulation of at least 1 food product proving quality, stability, nutritional and sensorial properties. Additional aspects related to prevention of intolerances/allergies, improved palatability and digestibility, health benefits, etc. are also in scope depending on the ingredient(s), formulation(s) and product(s) developed. Address resource efficiency and circularity aspects to increase economic and socio-environmental added value. When pursuing circular models, ensure that neither pathogens nor contaminants are injected back in the loop, to avoid negative toxicological effects. In addition to the specific requirements applicable for the type of action, as described in section 2.2.3.1 of the CBE JU Annual Work Programme 2026 [3] , proposals under this topic should: Assess the safety of developed nutritional food ingredients, in line with EU regulatory requirements and EFSA guidance documents. Moreover, identify potential EU regulatory gaps and propose recommendations to relevant EU policymakers on how to better support food ingredient companies (including startups and scaleups) in addressing EFSA risk assessment. As part of the multi-actor approach (MAA), involve end-users (including consumers) and other relevant actors starting from the early stages to gather input, raise awareness and ultimately foster market acceptance of the targeted end-products and incorporate insights into product development. Ensure complementarities and avoid overlaps with Programme areas: Global Challenges and European Industrial Competitiveness, Food, Bioeconomy Natural Resources, Agriculture and Environment, Bio-based Innovation Systems in the EU Bioeconomy, Horizon Europe (HORIZON) Keywords: Agricultural biotechnology and food biotechnology, Agricultural engineering, food safety, Food biotechnology, alternative sources, carbohydrates, circular economy, fibres, food ingredients, food products, food safety, lipids, nutrition, proteins, STEP-Biotech

IHI European HealthCare Incubator Network is sponsored by European Commission — Horizon Europe. Expected Impact: The action under this topic is expected to achieve the following impacts and contribute to the following EU policies/initiatives: deliver innovative, early technology solutions that contribute to addressing strategic unmet public health needs across multiple therapy areas to improve prevention, early diagnosis, and treatment; leverage the unique network and scale of IHI JU members to create a pipeline to support innovative startups in the health industry, fully integrated into European initiatives in support of start-ups and entrepreneurship; drive early cross-sector health R&D and innovation to strengthen the European healthcare industry’s global competitiveness, contributing to the EU Industrial Strategy and Pharmaceutical Strategy objectives; create a sustainable network of European healthcare incubators to guide and support highly talented and innovative early-stage companies; harness digital health and data-sharing technologies (e.g., AI and big data) to enable interoperable health solutions, contributing to the European Health Data Space (EHDS) and improved evidence based care;- the action should generate a portfolio of early‑stage companies that have undergone rigorous multi‑industry validation, significantly increasing their credibility with investors, regulators, and healthcare systems. This ‘industry quality seal’ should enhance the selected startups’ ability to secure follow‑on financing; by integrating corporate expertise into a pan‑European incubator network, the action should reduce fragmentation, support faster clinical and eventually commercial decision‑making, and enable more innovators to navigate regulatory and reimbursement pathways successfully. This should contribute to the objectives of the EU to accelerate the translation of research into deployable health technologies. The Network should serve as a feeder mechanism into wider EU support structures, ensuring that promising companies can transition smoothly into later‑stage funding and scale‑up opportunities. This complementarity should maximise the added value of EU public funding while avoiding duplication and reinforcing Europe’s position as a globally competitive hub for health innovation. The action under this topic should synergise with relevant EU programmes and contribute to several key EU strategies and policies: Life Science strategy, the proposed Biotech Act (especially the biotechnology development accelerators as referred to in article 5 of the Commission proposal), Industrial strategy, Pharmaceutical strategy, EU4Health Programme, Digital Europe Programme, Testing and Experimental Facility for Health AI and Robotic (TEF-Health), European Innovation Council (EIC) programmes, EU Competitive Compass, Choose Europe initiative, Startup and Scale-up strategy by the European Commission. Additionally, the action under this topic should synergise with the forthcoming European Startup and Scaleup Hubs and, in particular, encourage connection into the Network from the Call ‘European Startup and Scaleup Hub Pilot Call – HORIZON-EIE-2026-02-CONNECT-01’. Furthermore, the action has the potential to support Europe’s Beating Cancer Plan, EU Mission on Cancer, Healthier Together – EU Non-Communicable diseases initiative, Joint Action for Cardiovascular Disease and Diabetes in Europe, or the Cardiovascular Health Plan. Applicants should demonstrate in the proposal how these synergies will avoid duplication, ensure complementarity with existing EU efforts, and provide early-stage companies with continuity and scale up pathways. Expected Outcome: This call topic responds to the pressing need for a collaborative approach to accelerating the research-to-market pathway and fostering innovation and competitiveness in the European healthcare sector. Accordingly, the action under this topic must contribute to all of the following outcomes: 1. A sustainable European HealthCare Incubator Network (hereafter, the ‘Network’) linking incubators from t Programme areas: Global Challenges and European Industrial Competitiveness, Health, Innovative Health Initiative, Horizon Europe (HORIZON) Keywords: Competitiveness, innovation, research and development, Decrease technological and industrial risks, Health care, Incubator companies, Investment readiness, Related to SME and start-up support, SME support, Start-up companies, European HealthCare Incubator Network, IHI, IHI JU, Innovative Health Initiative, Innovative Health Initiative Joint Undertaking, Joint Undertaking Deadline stages: 2026-10-08, 2027-04-21